Skip to content

Role of Left Stellate Ganglion Block in Offering Myocardial Protection in On-pump Mitral Valve Replacement? A Histopathological and Clinical Assessment

Role of Left Stellate Ganglion Block in Offering Myocardial Protection in On-pump Mitral Valve Replacement? A Histopathological and Clinical Assessment

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06476925
Enrollment
62
Registered
2024-06-27
Start date
2024-07-15
Completion date
2025-03-20
Last updated
2026-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open Mitral Cardiac Surgery

Brief summary

Can pre-operative left stellate ganglion block offer myocardial protection in on-pump mitral valve replacement? A histopathological and clinical assessment.

Interventions

PROCEDUREsonar guided stellate ganglion injection

using high frequency probe, sonar guided stellate ganglion block with 8 ml saline 0.9%

PROCEDUREsonar guided stellate ganglion block

using high frequency probe, sonar guided stellate ganglion block with 8 ml bupivacaine 0.25%

Sponsors

Minia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
25 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Adult population of both sex, between 25-50 years, will undergo elective on pump mitral valve replacement

Exclusion criteria

* -Combined valve replacement ( mitral and aortic or mitral and tricuspid valves replacement). * Emergency valve replacement ( stuck valve, infective endocarditis). * Pre-operative cardiomyopathy (Ejection fraction less than 45%). * Recent myocardial infarction ( within 6 months) * Redo mitral valve replacement. * Pre-operative pacing, or cardioverter, any form arrhythmia ( tachy or brady). * Previous history of carotid endarterectomy or presence of carotid stent. * On thrombolytic therapy. * Severe chronic obstructive airway disease, * Patient refusal

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with microscopic myocardial injuryintra-operativeBiopsy from left papillary muscle to investigate microscopic evidence of cellular injury ( cytoplasmic oedema, hemorrhage and necrosis).

Secondary

MeasureTime frameDescription
Intra-operative arrhythmiaintraoperativelyincidence of intraoperative atrial fibrillation
postoperative arrhythmiafirst, second and third day after bypassIncidence of post operative atrial or ventricular arrhythmia
Troponin Ibefore operation, immediately after ICU admission and 3 days post-operativeSerum troponin I to diagnose myocardial injury
Myocardial functionpre-operative, one weekEjection fraction
weaning from mechanical ventilation24 hours post-operativeTime from ICU admission till successful extubation
Time of cardiopulmonary bypassIntraoperative
Length of ICU stayone week
Need for pacingintraoperative and one week after

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026